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Background: Primary adrenocortical insufficiency or Addison’s disease is caused by a progressive destruction of the
adrenal cortex, resulting into a reduction of glucocorticoids, mineralocorticoids, and androgens. Autoimmune
Addison’s disease is the most common etiological form, accounting for about 80% of all cases.
Case presentation: We describe the case of a 16-year-old Caucasian boy affected by type-1 diabetes mellitus and
autoimmune thyroiditis, who experienced recurrent hypoglycaemia as presenting symptom of Addison’s disease.
Conclusions: Hypoglycaemia is not a common presenting feature of Addison’s disease, both in patients with
type-1 diabetes mellitus and in non-diabetic patients. However, hypoglycaemia may occur in association with
primary and secondary glucocorticoid deficiency as a result of an enhanced insulin sensitivity. Hypoglycaemia is the
most common acute complication of insulin therapy in patients with type-1 diabetes mellitus. Addison’s disease
has been described in approximately 0.5% of patients with type-1 diabetes mellitus, being more frequent in females
and occurring in middle-aged patients. An association among type-1 diabetes mellitus, autoimmune thyroiditis, and
Addison’s disease is found in the “Schmidt’s syndrome”, a rare disorder that may occur in the paediatric age. Our
case suggests that the presence of Addison’s disease should be taken into consideration in patients with type-1
diabetes mellitus and frequent episodes of hypoglycaemia. We wish to highlight that there are no specific indications
to screen for the association between Addison’s disease and type-1 diabetes mellitus, although an early diagnosis of
Addison’s disease in diabetic patients would prevent the morbidity and potential mortality of this association.
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Primary adrenocortical insufficiency, named Addison’s
disease (AD), is caused by hypofunction/dysfunction of
the adrenal cortex, resulting into a reduced production
of glucocorticoids, mineralocorticoids and androgens as-
sociated with high levels of adreno-corticotrophic hormone
(ACTH) and high plasma renin activity. Autoimmune AD
is the most frequent form of AD in adult patients (about
80% of all cases), followed by post-tuberculosis AD (10–
15% of cases). Vascular, neoplastic or rare genetic forms
of AD account for 5% of cases [1]. Autoimmune AD is
commonly associated with other autoimmune diseases,
as occurs, for example, in types 1 and −2 autoimmune* Correspondence: manuela.caruso@policlinico.unict.it
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unless otherwise stated.polyendocrine syndromes (APS) [2]. The prevalence of
AD is 110–144 cases per million in developed countries.
The rate is significantly increased in patients with type-
1 diabetes mellitus (T1DM) [3,4]. Cortisol deficiency in-
creases insulin sensitivity resulting into an increased
peripheral glucose utilisation, impaired gluconeogene-
sis, and decreased hepatic glucose output [5]. Hence,
hypoglycaemia is expected to be a prominent and early
feature of AD in diabetic patients. Although early diag-
nosis of AD in diabetes would prevent the morbidity
and potential mortality of this association, there are not
specific indications for the screening of AD in T1DM
patients [6].
We describe the case of a young patient with T1DM
and autoimmune thyroiditis with recurrent episodes of
hypoglycaemia associated with the onset of AD.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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A 16-year-old Caucasian boy had been affected by T1DM
since the age of 16 months. The diagnosis of insulin-
dependent diabetes was confirmed by the following auto-
immune profile: glutamic acid decarboxylase antibodies
(GADA), 134 IU/ml; islet cell antibodies (ICA), 126 IU/
ml; and antibodies directed towards protein tyrosine
phosphatase-like protein (IA2-ab), 12 IU/ml. At the age of
4 years, autoimmune thyroiditis was diagnosed and treat-
ment with levo-tiroxine was started. In the last 4 years,
the patient had been treated with continuous subcutane-
ous insulin infusion (CSII), which, combined with an ad-
equate lifestyle (balanced diet and daily physical activity),
allowed to obtain an optimal glycaemic control.
During a follow-up visit, he reported sporadic episodes
of hypoglycaemia in the preceding three months; one of
these episodes was severe with loss of consciousness, and
required admission to the hospital. At physical examin-
ation we observed: height = 180 cm; weight = 67 kg; body
mass index (BMI) = 20.7 Kg/m2; blood pressure = 120/
75 mmHg. General examination showed no abnormalities.
Glycated haemoglobin was 7.5%. The patient was on a
total daily insulin dose of 1.1 IU/Kg/day, with a percentage
of basal insulin of 41%. We prescribed a reduction of the
total insulin dose, and the insulin/carbohydrate ratio was
reset, reassessing patient’s food diary.
The patient was revaluated three months later: other
episodes of hypoglycaemia had occurred with one epi-
sode of severe hypoglycaemia characterized by seizure
and treated with glucagon. At physical examination,
body weight was unchanged; blood pressure was 105/
55 mmHg, and glycated haemoglobin was significantly
reduced (6.6%). General examination revealed no clinical
signs indicative of any associated disease. The patient,
spontaneously, had gradually reduced basal insulin (total
0.92 IU/kg/day) and had continued to show an adequate
compliance with dietetic and therapeutic regimens. Both
the patient and his parents denied alcohol abuse or im-
proper lifestyle. Routine blood chemistry resulted nega-
tive, excluding the presence of liver and kidney diseases.
Screening for celiac disease was also negative. Hence, we
decided to further reduce the total dose of insulin.
At the following visit, the patient reported frequent
hypoglycaemic episodes and marked asthenia. The clinical
picture appeared clearly deteriorated: a significant weight
loss was observed (weight 61 kg; BMI 18.7 Kg/m2). Down-
loaded data of the insulin pump indicated a further reduc-
tion of total insulin by more than 30% (0.75 IU/kg/day).
Glycated haemoglobin value was 6.3%. At clinical examin-
ation, the patient presented scrotal hyperpigmentation
and blood pressure = 80/50 mmHg.
Adrenal insufficiency was immediately suspected, and
the patient was admitted to the hospital for further in-
vestigation. Blood tests showed: sodium, 129 mEq/L(136–145); potassium, 5.3 mEq/L (3.5-5.1); basal serum
cortisol, 1.5 ng/ml; ACTH, 1274 pg/ml (<60). Blood corti-
sol levels in response to the ACTH test (1 μg i.v.) were the
following: basal levels, 1.5 ng/ml; levels at 20’, 1.1 ng/ml;
and levels at 30’, 1.1 ng/ml. Adrenal antibodies could be
detected.
The diagnosis of AD was confirmed and cortisone
acetate (14 mg/m2 in three doses) was prescribed.
Discussion
Hypoglycaemia is the most common acute complication in
patients with T1DM. It is the main side effect of insulin
therapy and an important limiting factor in the manage-
ment of T1DM [7,8]. Our case shows how the clinical ap-
proach to patients with T1DM and frequent hypoglycaemia
should include the search for AD. Hypoglycaemia is not a
common presenting feature of AD regardless of the pres-
ence of T1DM, although it has been associated with both
primary and secondary glucocorticoid deficiency as a result
of an enhanced insulin sensitivity [9]. Therefore, particu-
larly in patients presenting abrupt reduction of insulin
requirements and good compliance for dietetic and
therapeutic regimens, the diagnosis of AD should be
considered after excluding other potential causes of
hypoglycaemia, such as excessive physical activity, sig-
nificant reduction of carbohydrate intake, alcohol abuse,
intestinal malabsorption, chronic renal failure, and liver
disease. We did not measure insulin antibodies, which
could be an additional cause of hypoglycaemia in our
patient. Non-neutralizing insulin-binding antibodies in-
duced by exogenous insulin may prolong the half-life of
insulin in the circulation, thereby lowering insulin require-
ment [10,11]. Insulin binding to antibodies has been con-
sidered as a risk factor for inexplicable hypoglycaemia in
T1DM children [12].
Primary adrenocortical insufficiency or AD is caused
by a progressive destruction of the adrenal cortex, result-
ing into a reduction of cortisol and aldosterone in both
sexes, and a reduction of androgens in women [13]. The
prevalence of AD is 110–144 cases per million in developed
countries. Autoimmune AD is the most common etio-
logical form of AD and may occur alone or be associated
with other clinical, subclinical or potential autoimmune dis-
eases, giving rise to various forms of autoimmune poly-
glandular syndrome (types 1, 2, or 4) [1]. AD is described
in approximately 0.5% of patients with T1DM [3,4]: it is
more frequent in females and occurs in middle-aged pa-
tients, usually several years after the onset of T1DM [14].
T1DM, thyroiditis, and AD are associated in a clinical
disorder known as Schmidt’s syndrome or type 2 auto-
immune polyglandular syndrome (APS-II). The mean age
at onset of Schmidt’s syndrome is about 30 years. Schmidt’s
syndrome has an estimated prevalence of 1:200,000, and is
very rare in the paediatric age [15]. However, an early onset
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ticipate the disease [16].
To date, there are no national or international clear
guidelines on the advisability of AD screening in paediat-
ric diabetic patients.
Recent studies have demonstrated that 21 -hydroxylase
autoantibodies (21OH-AA) have a low predictive value
because the appearance of autoantibodies could anticipate
the onset of the disease by many years. In addition, only
90% of T1DM patients with AD are 21OH-AA positive
[17]. Moderately increased ACTH levels may be consid-
ered as an useful early indicator of AD, regardless of basal
serum cortisol levels [6]. This data could identify those pa-
tients that should undergo a corticotrophin-stimulation
test for the diagnosis of AD.
Conclusions
The rarity of AD makes annual screening procedure un-
economic in patients with T1DM. The frequency of the
screening procedure should depend on the characteristics
of the patient. A diagnosis of T1DM in the first years of
life and the coexistence of other autoimmune disorders,
particularly autoimmune thyroiditis, should prompt to a
closer inspection. Measurements of basal cortisol and
ACTH levels should be immediately performed in patients
with clinical suspect of AD. We wish to highlight that re-
current hypoglycaemia can be the only presenting feature
of adrenal insufficiency, and, therefore, should encourage
the examination of adrenal function. An early diagnosis of
AD in T1DM patients is advisable to reduce morbidity
and mortality in these patients.
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